New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Nektar Therapeutics (NKTR) presented data at EADV Congress 2026 showing early molecular responses to rezpegaldesleukin in atopic dermatitis patients. The drug demonstrated significant biomarker changes by Week 2, correlating with clinical improvement. The Phase 2b REZOLVE-AD study involved 100 patients, with a 64% reduction in EASI score at Week 16 in the molecular cohort. Rezpegaldesleukin targets the IL-2 receptor to stimulate regulatory T cells, aiming to restore immune balance.
How this was made
The 30-second read
Why it matters
The presented biomarker data provide mechanistic validation and early efficacy signals, potentially de‑risking the program and supporting a higher valuation for NKTR.
Market read
First‑time release of multi‑omic data for a novel immunology therapy; could move NKTR stock and influence peer biotech valuations.
What to watch
Fast Track designations and upcoming regulatory milestones could amplify upside if data hold up.
Background
Rezpegaldesleukin is a first‑in‑class regulatory T‑cell biologic targeting IL‑2R, currently in Phase 2b REZOLVE‑AD for moderate‑to‑severe atopic dermatitis.
Ticker impact
Nektar Therapeutics (NASDAQ: NKTR) presented new Phase 2b biomarker data for rezpegaldesleukin showing early molecular responses and correlation with clinical improvement in atopic dermatitis.
likely upward pressure as investors price in stronger efficacy data.
First disclosure of multi‑omic results, early Treg activation and significant EASI reduction, a material catalyst for a biotech with no prior data release.
Market effects
Strengthens the broader immunology/dermatology biotech sector by showing a novel Treg approach can yield early clinical signals.
May benefit US biotech indices and Nasdaq biotech ETFs.
Limited to investors focused on US-listed biotech firms.
Counterpoint
Early biomarker changes may not translate into durable clinical benefit; Phase 3 could still fail.
Key entities
- companyNektar Therapeutics
US‑listed biotech developing rezpegaldesleukin.
- institutionIcahn School of Medicine at Mount Sinai
Research collaborator on the biomarker sub‑study.
